AstraZeneca profit jumps 23% as it unveils major savings plan
Article excerpt
AstraZeneca, Britain's biggest pharmaceutical company, said on Friday that its profit after tax rose 23% to $3.12 billion (€2.79bn) for the July to September period, driven largely by its cancer treatments. That marks a sharp pick-up from the rise of just over 2% in the previous quarter. The firm also launched a plan to generate $1.5 billion (€1.34bn) in annual savings, which it intends to reinvest mainly in the drugs it has in development. Revenue grew 7% to $16.2 billion (€14.5bn). Oncology, its biggest business, accounted for 48% of the total, with sales up 17% to $7.8 billion (€6.99bn), led by lung cancer drug Tagrisso and immunotherapy Imfinzi. Core earnings per share, which exclude items such as restructuring costs and the amortisation of acquired drugs, rose 17% to $2.79. The savings drive, called Reshaping for Sustainable Growth, will cost up to $2 billion (€1.79bn) in one-off restructuring charges and is due to be largely complete by the end of 2029. AstraZeneca said the savings would be reinvested in the company, principally in its pipeline of new drugs, as it plans to "redeploy resources" across its existing business to back more than 180 projects in development. Such restructuring could mean job cuts, though none have been announced. "With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on...
Keep reading with a free account
The rest of this article, and every signal for AstraZeneca, is in your free account.
Extracted from this sentence
It has reported 12 positive results from late-stage trials so far this year, and is also developing a weight-loss treatment to compete with drugs such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro.
